The Bloomberg Advantage: Gordon on Pfizer Deal for Medivation
August 22, 2016•8 min
(Bloomberg) -- The Bloomberg Advantage with Carol Massar and Cory Johnson.
Ross School of Business at the University of Michigan
Discussing Pfizer beating out a group of rivals after months of jockeying to buy Medivation and its blockbuster cancer drug for $14 billion.